Home › Articles › Volume 8, Issue 4 › Outcome of Primary Small Cell Carcinoma of Esophagus...
Moradabad, India
Original Article
Medical Oncology

Outcome of Primary Small Cell Carcinoma of Esophagus: A Single Institutional Experience


Volume 8, Issue 4, Pages 4-9

Authors

Partha Sarathi Roy1, Bhargab Jyoti Saikia1, Satya S Sarangi1, Mouchumee Bhattacharyya2, Abhijit Talukdar3, Manoj Kalita4
Affiliation:
1Department of Medical Oncology,
2Department of Radiation Oncology,
3Department of Surgical Oncology,
4Department of Epidemiology and HBCR; Dr B Borooah Cancer Institute, Guwahati, Assam, India.

Corresponding Author

Bhargab Jyoti Saikia

Abstract

Background: Background and Objectives: Primary small cell carcinoma of esophagus (SCCE) is a very aggressive disease and accounts for 0.8–3.1% of all esophageal cancers. The study analysed clinical characteristics and survival outcome of 24 treated cases. Subjects & Methods: Out of total 3,440 cases of esophageal cancers diagnosed from 2013 to 2016 at Dr B Borooah Cancer Institute, clinical data were obtained from 24 histologically and immunohistochemically confirmed cases of primary SCCE. Patients received surgery, chemotherapy and/or radiotherapy, either alone or in combinations. Results: The median age of patients was 54 years with male preponderance. Out of 24 cases, 15 cases have pure small cell carcinoma histology and 9 cases had mixed pathology (poorly differentiated carcinoma with neuroendocrine differentiation). The median overall survival time was 14 months. The 6-, 12-, 24- and 36- month’s survival rates of these patients were 91.6%, 54.1%, 33.3% and 25.0% respectively. The 3-year survival rate for patients with localised disease was 62.6% vs. 6.3% for those with metastatic disease (p=0.007). Nine patients had relapses within first 6 months from the completion of any therapy. Patients with pure small cell carcinoma histology (vs. mixed histology, p=0.008), with distant organ involvement (vs. no organ involvement, p=0.022) and those who are non-responders to treatment (vs. responders, p<0.0001) were correlated with shorter overall survival in univariate analysis. Conclusion: Primary SCCE presents with early metastasis and have a poor prognosis, with the existing modalities of treatment. Combined therapy based on platinum-based combination chemotherapy may improve the short term survival in these patients.

Keywords

Small cell carcinoma, neuroendocrine tumor, combination chemotherapy, survival outcome.

History

Received 01 December 2019

Accepted 01 December 2019

DOI

10.21276/ajmr.2019.8.4.MC2

Author Notes

Corresponding Author: Dr Bhargab Jyoti Saikia, Professor, Dept. of Medical Oncology, Dr B Borooah Cancer Institute, A. K. Azad Road, Gopinath Nagar, Guwahati, PIN – 781016, Assam, India.

Open Access

It is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits authors to retain ownership of the copyright for their content, and allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. https://creativecommons.org/licenses/by/4.0/

Copyright

Copyright: © the author(s), 2019.

Cite this Article

Formats

                                                
Actions
Download PDF
Metrics
7
Downloads
7
Views
Journal
Journal Asian Journal of Medical Research
Volume Volume 8
Issue Issue 4
Year 2019

Purchase access plans

Select the plan that best fits your need

Loading plans...

Statistics:

Views: 0
Downloads: 0

Asian Journal of Medical Research (AJMR) is an international, peer-reviewed, quarterly open-access journal publishing advanced research across medical specialties.

Quick Links

For Authors

© 2026 Asian Journal of Medical Research. All Rights Reserved.Designed and Developed By Kryoni